Navigation Links
Acidic tumor pH inhibits drug effect
Date:2/11/2014

Low pH in tumours counteracts the desired effect of the drug chloroquine, according to a new study from Karolinska Institutet in Sweden. The results, which are published in the journal Autophagy, might explain possible lack of efficacy of chloroquine in clinical studies.

Chloroquine, a widely used antimalaria drug, is currently under investigation in clinical trials on cancer patients. It is the ability of chloroquine to inhibit autophagy in tumour cells that has piqued researchers' interest. Autophagy is a homeostatic process by which cells eat parts of themselves, so that damaged or unnecessary organelles and toxic proteins are broken down and recycled. In the absence of nutrients, cells resort to autophagy to survive. This way, autophagy helps cancer cells survive in tumour regions that are poor in nutrients and characterised by low oxygen and acidic pH.

Also, tumour cells use autophagy to protect themselves from many forms of anticancer therapies, including chemotherapy. Several studies have shown that inhibition of autophagy often increases chemosensitivity and radiosensitivity in tumour cells. Chloroquine combined with existing cancer treatment is thus considered to be a promising strategy. However, in some cancer models chloroquine seems to be unable to block autophagy, but the underlying mechanisms have not yet been identified.

In the present study, the scientists studied the effect of chloroquine in different cancer cells that were either cultured in acidic pH for a short time or adapted to chronic acidosis. The researchers also studied the effect in tumours grown in mice.

We discovered that a major consequence of the altered metabolism of tumour cells, the tissue acidification, is responsible for the lack of chloroquine anti-autophagic activity. The results suggest that chloroquine might lack efficacy in patients whose tumours are characterised by acidic regions, says Angelo De Milito at the Department of Oncology-Pathology at Karolinska Institutet, principal investigator of the study.

In the context of cancer therapy, the finding may be of importance for the translation of preclinical findings to the clinical setting in patients. The research was funded by Association for International Cancer Research, the Swedish Cancer Society, and the Sigurd and Elsa Goljes Foundation.


'/>"/>

Contact: Press Office
pressinfo@ki.se
46-852-486-077
Karolinska Institutet
Source:Eurekalert  

Related biology news :

1. Corals could survive a more acidic ocean
2. Cystic fibrosis makes airways more acidic, reduces bacterial killing
3. Glimpse into the future of acidic oceans shows ecosystems transformed
4. New studies needed to predict how marine organisms may adapt to the futures acidic oceans
5. The loss of a protein makes jump the tumor to the lymph node
6. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
7. Dental X-rays linked to common brain tumor
8. TGen leads new National Institutes of Health study of brain tumors
9. Immune-response genes affecting breast tumor eradication
10. A single stem cell mutation triggers fibroid tumors
11. Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Acidic tumor pH inhibits drug effect
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology: